Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase 3 study of thymosin beta 4 (RGN 259) for Dry eyes : ARISE-3.

Trial Profile

A pivotal phase 3 study of thymosin beta 4 (RGN 259) for Dry eyes : ARISE-3.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms ARISE-3
  • Sponsors ReGenTree
  • Most Recent Events

    • 12 Feb 2019 Status changed from planning to recruiting, according to a RegeneRx Biopharmaceuticals media release.
    • 12 Feb 2019 According to a RegeneRx Biopharmaceuticals media release, treatment of the subjects in the trial will be completed in the first half of 2020.
    • 04 Jan 2019 According to a RegeneRx Biopharmaceuticals media release, Gtree is not designing ARISE-3 to do more than the FDA requires for products currently on the market.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top